Anti-SARS-CoV-2 antibody dynamics after primary vaccination with two-dose inactivated whole-virus vaccine, heterologous mRNA-1273 vaccine booster, and Omicron breakthrough infection in Indonesian health care workers
Background: Data on the dynamics and persistence of humoral immunity against SARS-CoV-2 after primary vaccination with two-dose inactivated vaccine (CoronaVac) are limited. This study evaluated the sequential effects of prior infection, heterologous boosting with mRNA-1273 (Moderna), and the occurre...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
BioMed Central
2024
|
| _version_ | 1817930972969041920 |
|---|---|
| author | Suwarti, S Lazarus, G Zanjabila, S Sinto, R Fransiska, F Deborah, T Oktavia, D Junaidah, J Santayana, S Surendra, H Yuliana, J Pardosi, H Nuraeni, N Soebianto, S Susilowati, ND Subekti, D Pradipta, A Baird, JK Tan, LV Dunachie, S Shankar, AH Nelwan, EJ Hamers, RL |
| author_facet | Suwarti, S Lazarus, G Zanjabila, S Sinto, R Fransiska, F Deborah, T Oktavia, D Junaidah, J Santayana, S Surendra, H Yuliana, J Pardosi, H Nuraeni, N Soebianto, S Susilowati, ND Subekti, D Pradipta, A Baird, JK Tan, LV Dunachie, S Shankar, AH Nelwan, EJ Hamers, RL |
| author_sort | Suwarti, S |
| collection | OXFORD |
| description | Background: Data on the dynamics and persistence of humoral immunity against SARS-CoV-2 after primary vaccination with two-dose inactivated vaccine (CoronaVac) are limited. This study evaluated the sequential effects of prior infection, heterologous boosting with mRNA-1273 (Moderna), and the occurrence of Omicron vaccine-breakthrough infection (VBI) thereafter. Methods: We evaluated anti-spike IgG (Abbott) and neutralising (cPASS/GenScript) antibody (nAb) titers up to one year after mRNA-1273 boost in two-dose-CoronaVac-primed Indonesian healthcare workers (August 2021-August 2022). We used linear mixed modeling to estimate the rate of change in antibody levels, and logistic regression to examine associations between antibody levels and VBI. Results: Of 138 participants, 52 (37.7%) had a prior infection and 78 (56.5%) received an mRNA-1273 booster. After two-dose CoronaVac, antibody titers had significantly declined within 180 days, irrespective of prior infection. After mRNA-1273 booster, anti-spike IgG (1.47% decline/day) and Omicron B.1.1.529/BA.2 nAbs declined between day 28–90, and IgG titers plateaued between day 90–360. During the BA.1/BA.2 wave (February–March 2022), 34.6% (27/78) of individuals experienced a VBI (median 181 days after mRNA-1273), although none developed severe illness. VBI was associated with low pre-VBI anti-spike IgG and B.1.1.529/BA.2 nAbs, which were restored post-VBI. Conclusions: mRNA-1273 booster after two-dose CoronaVac did not prevent BA.1/BA.2 VBI. Periodic vaccine boosters may be warranted against emerging SARS-CoV-2 variants. |
| first_indexed | 2024-09-25T04:20:11Z |
| format | Journal article |
| id | oxford-uuid:369b8f2e-14e4-4e36-b4d7-54c531240629 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-12-09T03:14:37Z |
| publishDate | 2024 |
| publisher | BioMed Central |
| record_format | dspace |
| spelling | oxford-uuid:369b8f2e-14e4-4e36-b4d7-54c5312406292024-10-16T09:42:15ZAnti-SARS-CoV-2 antibody dynamics after primary vaccination with two-dose inactivated whole-virus vaccine, heterologous mRNA-1273 vaccine booster, and Omicron breakthrough infection in Indonesian health care workersJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:369b8f2e-14e4-4e36-b4d7-54c531240629EnglishJisc Publications RouterBioMed Central2024Suwarti, SLazarus, GZanjabila, SSinto, RFransiska, FDeborah, TOktavia, DJunaidah, JSantayana, SSurendra, HYuliana, JPardosi, HNuraeni, NSoebianto, SSusilowati, NDSubekti, DPradipta, ABaird, JKTan, LVDunachie, SShankar, AHNelwan, EJHamers, RLBackground: Data on the dynamics and persistence of humoral immunity against SARS-CoV-2 after primary vaccination with two-dose inactivated vaccine (CoronaVac) are limited. This study evaluated the sequential effects of prior infection, heterologous boosting with mRNA-1273 (Moderna), and the occurrence of Omicron vaccine-breakthrough infection (VBI) thereafter. Methods: We evaluated anti-spike IgG (Abbott) and neutralising (cPASS/GenScript) antibody (nAb) titers up to one year after mRNA-1273 boost in two-dose-CoronaVac-primed Indonesian healthcare workers (August 2021-August 2022). We used linear mixed modeling to estimate the rate of change in antibody levels, and logistic regression to examine associations between antibody levels and VBI. Results: Of 138 participants, 52 (37.7%) had a prior infection and 78 (56.5%) received an mRNA-1273 booster. After two-dose CoronaVac, antibody titers had significantly declined within 180 days, irrespective of prior infection. After mRNA-1273 booster, anti-spike IgG (1.47% decline/day) and Omicron B.1.1.529/BA.2 nAbs declined between day 28–90, and IgG titers plateaued between day 90–360. During the BA.1/BA.2 wave (February–March 2022), 34.6% (27/78) of individuals experienced a VBI (median 181 days after mRNA-1273), although none developed severe illness. VBI was associated with low pre-VBI anti-spike IgG and B.1.1.529/BA.2 nAbs, which were restored post-VBI. Conclusions: mRNA-1273 booster after two-dose CoronaVac did not prevent BA.1/BA.2 VBI. Periodic vaccine boosters may be warranted against emerging SARS-CoV-2 variants. |
| spellingShingle | Suwarti, S Lazarus, G Zanjabila, S Sinto, R Fransiska, F Deborah, T Oktavia, D Junaidah, J Santayana, S Surendra, H Yuliana, J Pardosi, H Nuraeni, N Soebianto, S Susilowati, ND Subekti, D Pradipta, A Baird, JK Tan, LV Dunachie, S Shankar, AH Nelwan, EJ Hamers, RL Anti-SARS-CoV-2 antibody dynamics after primary vaccination with two-dose inactivated whole-virus vaccine, heterologous mRNA-1273 vaccine booster, and Omicron breakthrough infection in Indonesian health care workers |
| title | Anti-SARS-CoV-2 antibody dynamics after primary vaccination with two-dose inactivated whole-virus vaccine, heterologous mRNA-1273 vaccine booster, and Omicron breakthrough infection in Indonesian health care workers |
| title_full | Anti-SARS-CoV-2 antibody dynamics after primary vaccination with two-dose inactivated whole-virus vaccine, heterologous mRNA-1273 vaccine booster, and Omicron breakthrough infection in Indonesian health care workers |
| title_fullStr | Anti-SARS-CoV-2 antibody dynamics after primary vaccination with two-dose inactivated whole-virus vaccine, heterologous mRNA-1273 vaccine booster, and Omicron breakthrough infection in Indonesian health care workers |
| title_full_unstemmed | Anti-SARS-CoV-2 antibody dynamics after primary vaccination with two-dose inactivated whole-virus vaccine, heterologous mRNA-1273 vaccine booster, and Omicron breakthrough infection in Indonesian health care workers |
| title_short | Anti-SARS-CoV-2 antibody dynamics after primary vaccination with two-dose inactivated whole-virus vaccine, heterologous mRNA-1273 vaccine booster, and Omicron breakthrough infection in Indonesian health care workers |
| title_sort | anti sars cov 2 antibody dynamics after primary vaccination with two dose inactivated whole virus vaccine heterologous mrna 1273 vaccine booster and omicron breakthrough infection in indonesian health care workers |
| work_keys_str_mv | AT suwartis antisarscov2antibodydynamicsafterprimaryvaccinationwithtwodoseinactivatedwholevirusvaccineheterologousmrna1273vaccineboosterandomicronbreakthroughinfectioninindonesianhealthcareworkers AT lazarusg antisarscov2antibodydynamicsafterprimaryvaccinationwithtwodoseinactivatedwholevirusvaccineheterologousmrna1273vaccineboosterandomicronbreakthroughinfectioninindonesianhealthcareworkers AT zanjabilas antisarscov2antibodydynamicsafterprimaryvaccinationwithtwodoseinactivatedwholevirusvaccineheterologousmrna1273vaccineboosterandomicronbreakthroughinfectioninindonesianhealthcareworkers AT sintor antisarscov2antibodydynamicsafterprimaryvaccinationwithtwodoseinactivatedwholevirusvaccineheterologousmrna1273vaccineboosterandomicronbreakthroughinfectioninindonesianhealthcareworkers AT fransiskaf antisarscov2antibodydynamicsafterprimaryvaccinationwithtwodoseinactivatedwholevirusvaccineheterologousmrna1273vaccineboosterandomicronbreakthroughinfectioninindonesianhealthcareworkers AT deboraht antisarscov2antibodydynamicsafterprimaryvaccinationwithtwodoseinactivatedwholevirusvaccineheterologousmrna1273vaccineboosterandomicronbreakthroughinfectioninindonesianhealthcareworkers AT oktaviad antisarscov2antibodydynamicsafterprimaryvaccinationwithtwodoseinactivatedwholevirusvaccineheterologousmrna1273vaccineboosterandomicronbreakthroughinfectioninindonesianhealthcareworkers AT junaidahj antisarscov2antibodydynamicsafterprimaryvaccinationwithtwodoseinactivatedwholevirusvaccineheterologousmrna1273vaccineboosterandomicronbreakthroughinfectioninindonesianhealthcareworkers AT santayanas antisarscov2antibodydynamicsafterprimaryvaccinationwithtwodoseinactivatedwholevirusvaccineheterologousmrna1273vaccineboosterandomicronbreakthroughinfectioninindonesianhealthcareworkers AT surendrah antisarscov2antibodydynamicsafterprimaryvaccinationwithtwodoseinactivatedwholevirusvaccineheterologousmrna1273vaccineboosterandomicronbreakthroughinfectioninindonesianhealthcareworkers AT yulianaj antisarscov2antibodydynamicsafterprimaryvaccinationwithtwodoseinactivatedwholevirusvaccineheterologousmrna1273vaccineboosterandomicronbreakthroughinfectioninindonesianhealthcareworkers AT pardosih antisarscov2antibodydynamicsafterprimaryvaccinationwithtwodoseinactivatedwholevirusvaccineheterologousmrna1273vaccineboosterandomicronbreakthroughinfectioninindonesianhealthcareworkers AT nuraenin antisarscov2antibodydynamicsafterprimaryvaccinationwithtwodoseinactivatedwholevirusvaccineheterologousmrna1273vaccineboosterandomicronbreakthroughinfectioninindonesianhealthcareworkers AT soebiantos antisarscov2antibodydynamicsafterprimaryvaccinationwithtwodoseinactivatedwholevirusvaccineheterologousmrna1273vaccineboosterandomicronbreakthroughinfectioninindonesianhealthcareworkers AT susilowatind antisarscov2antibodydynamicsafterprimaryvaccinationwithtwodoseinactivatedwholevirusvaccineheterologousmrna1273vaccineboosterandomicronbreakthroughinfectioninindonesianhealthcareworkers AT subektid antisarscov2antibodydynamicsafterprimaryvaccinationwithtwodoseinactivatedwholevirusvaccineheterologousmrna1273vaccineboosterandomicronbreakthroughinfectioninindonesianhealthcareworkers AT pradiptaa antisarscov2antibodydynamicsafterprimaryvaccinationwithtwodoseinactivatedwholevirusvaccineheterologousmrna1273vaccineboosterandomicronbreakthroughinfectioninindonesianhealthcareworkers AT bairdjk antisarscov2antibodydynamicsafterprimaryvaccinationwithtwodoseinactivatedwholevirusvaccineheterologousmrna1273vaccineboosterandomicronbreakthroughinfectioninindonesianhealthcareworkers AT tanlv antisarscov2antibodydynamicsafterprimaryvaccinationwithtwodoseinactivatedwholevirusvaccineheterologousmrna1273vaccineboosterandomicronbreakthroughinfectioninindonesianhealthcareworkers AT dunachies antisarscov2antibodydynamicsafterprimaryvaccinationwithtwodoseinactivatedwholevirusvaccineheterologousmrna1273vaccineboosterandomicronbreakthroughinfectioninindonesianhealthcareworkers AT shankarah antisarscov2antibodydynamicsafterprimaryvaccinationwithtwodoseinactivatedwholevirusvaccineheterologousmrna1273vaccineboosterandomicronbreakthroughinfectioninindonesianhealthcareworkers AT nelwanej antisarscov2antibodydynamicsafterprimaryvaccinationwithtwodoseinactivatedwholevirusvaccineheterologousmrna1273vaccineboosterandomicronbreakthroughinfectioninindonesianhealthcareworkers AT hamersrl antisarscov2antibodydynamicsafterprimaryvaccinationwithtwodoseinactivatedwholevirusvaccineheterologousmrna1273vaccineboosterandomicronbreakthroughinfectioninindonesianhealthcareworkers |